Valentina Mazzotta Selected Research

COVID-19

5/2024	Molnupiravir increases SARS-CoV-2 genome diversity and complexity: A case-control cohort study.
4/2024	SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV.
4/2024	Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era.
4/2024	Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.
2/2024	Impact of COVID-19 pandemic on retention in care of native and migrant people with HIV in the ICONA cohort.
1/2024	Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia.
10/2023	SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio.
10/2023	Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA.4/5 Outpatients.
9/2023	Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV.
3/2023	What is the impact of post-COVID-19 syndrome on health-related quality of life and associated factors: a cross-sectional analysis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Valentina Mazzotta Research Topics

Disease

17	COVID-19 05/2024 - 01/2021
11	Infections 04/2024 - 07/2014
7	HIV Infections (HIV Infection) 03/2024 - 01/2023
7	Mpox (monkeypox) 02/2024 - 01/2022
4	Acquired Immunodeficiency Syndrome (AIDS) 09/2023 - 01/2022
3	Smallpox (Variola) 02/2024 - 01/2023
3	Coinfection 12/2023 - 01/2017
2	Vaccinia 02/2024 - 11/2023
2	Pneumonia (Pneumonitis) 01/2024 - 03/2023
2	Communicable Diseases (Infectious Diseases) 11/2023 - 03/2023
2	Pain (Aches) 11/2023 - 07/2014
2	Proctitis 08/2023 - 05/2023
2	Respiratory Insufficiency (Respiratory Failure) 04/2021 - 01/2021
1	Human Influenza (Influenza) 05/2024
1	Breakthrough Infections 04/2024
1	Hematologic Diseases (Blood Diseases) 04/2024
1	Liver Diseases (Liver Disease) 12/2023
1	Liver Cirrhosis (Hepatic Cirrhosis) 12/2023
1	Disease Progression 10/2023
1	Inflammation (Inflammations) 08/2023
1	Sepsis (Septicemia) 08/2023
1	Necrosis 03/2023
1	Immune Reconstitution Inflammatory Syndrome 01/2023
1	Neurocognitive Disorders (Clerambault Syndrome) 01/2023
1	Progressive Multifocal Leukoencephalopathy 01/2022
1	Syphilis 10/2021
1	Venous Thromboembolism 01/2021
1	Latent Tuberculosis 03/2020
1	Viremia 01/2020
1	Hepatitis C 01/2017
1	Discitis 07/2014

Drug/Important Bio-Agent (IBA)

10	3- (2- methoxyphenyl)- 5- methoxy- 1,3,4- oxadiazol- 2(3H)- oneIBA 02/2024 - 12/2022
5	VaccinesIBA 02/2024 - 09/2023
4	Antiviral Agents (Antivirals)IBA 05/2024 - 01/2021
3	N-(2-cyanoethylene)urea (BA 1)IBA 04/2024 - 01/2023
3	tecovirimatIBA 11/2023 - 01/2023
3	mRNA VaccinesIBA 10/2023 - 01/2022
3	InterferonsIBA 09/2023 - 01/2017
2	molnupiravirIBA 05/2024 - 01/2023
2	cilgavimabIBA 04/2024 - 10/2023
2	tixagevimabIBA 04/2024 - 10/2023
2	smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordicIBA 02/2024 - 11/2023
2	Monoclonal AntibodiesIBA 01/2024 - 01/2023
2	Immunoglobulin G (IgG)IBA 01/2024 - 01/2023
2	casirivimab and imdevimab drug combinationIBA 01/2024 - 01/2022
2	RNA (Ribonucleic Acid)IBA 12/2023 - 10/2021
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 12/2023 - 01/2017
2	Cidofovir (Vistide)FDA Link 11/2023 - 01/2023
2	Viral DNAIBA 03/2023 - 01/2022
2	CytokinesIBA 03/2023 - 01/2021
1	Messenger RNA (mRNA)IBA 04/2024
1	MicroRNAs (MicroRNA)IBA 03/2024
1	Smallpox Vaccine (Vaccine, Smallpox)FDA Link 02/2024
1	Illicit Drugs (Recreational Drugs)IBA 11/2023
1	mutalipocin IIIBA 10/2023
1	AntibodiesIBA 10/2023
1	N 30IBA 09/2023
1	Combined VaccinesIBA 09/2023
1	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2023
1	Adenosine Monophosphate (AMP)IBA 03/2023
1	sarilumabIBA 03/2023
1	InterleukinsIBA 03/2023
1	Interleukin-8 (Interleukin 8)IBA 03/2023
1	Interleukin-6 (Interleukin 6)IBA 03/2023
1	Interleukin-6 InhibitorsIBA 03/2023
1	Immunoglobulin M (IgM)IBA 01/2023
1	Immunoglobulin A (IgA)IBA 01/2023
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2023
1	nirmatrelvir and ritonavir drug combinationIBA 01/2023
1	sotrovimabIBA 01/2023
1	remdesivirIBA 01/2023
1	Neutralizing AntibodiesIBA 01/2023
1	pembrolizumabIBA 01/2022
1	2019-nCoV Vaccine mRNA-1273IBA 01/2022
1	bamlanivimab and etesevimab drug combinationIBA 01/2022
1	BNT162 VaccineIBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	Viral RNAIBA 04/2021
1	fibrin fragment D (D-dimer)IBA 04/2021
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2021
1	Ritonavir (Norvir)FDA Link 01/2021
1	Lopinavir FDA Link 01/2021
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2017
1	sofosbuvir drug combination ledipasvirIBA 01/2017
1	Anti-Bacterial Agents (Antibiotics)IBA 07/2014

Therapy/Procedure

9	Therapeutics 04/2024 - 07/2014
3	Aftercare (After-Treatment) 05/2024 - 07/2014
3	Art Therapy 01/2023 - 01/2021
2	Artificial Respiration (Mechanical Ventilation) 01/2024 - 04/2021
1	Retention in Care 02/2024
1	Transplantation 12/2023
1	Braces 07/2014
1	Conservative Treatment 07/2014